Drug Trial Radar · NCT02992457
Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection
Last checked: Nov 19, 2026Latest source record: Aug 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10,000
Actual
Start
Jan 2015
Primary completion
Dec 2018
Study completion Dec 2019
Sponsor
- Lead sponsor
- Tanta UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 14, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Egypt has the highest prevalence of hepatitis C virus (HCV) in the world, estimated nationally at 14.7%. Genotype 4 (and subtype 4a in particular) dominates the HCV epidemic in Egypt. For decades the antiviral therapy of chronic HCV infection was based on the administration of Interferon(IFN), initially alone and then in combination with Ribavirin (RBV), but this regimen was effective in only 50% of patients with genotype 1, with significant side effects.
Conditions
- Hepatitis C
Interventions
SofosbuvirDrug
Sofosbuvir 400 mg daily.
RibavirinDrug
Ribavirin 1000-1200 mg daily
Pegylated-interferon alfa-2aDrug
Pegylated interferon alfa-2a once weekly for 3 months
SimeprevirDrug
Olysio once daily.
DaclatasvirDrug
Dakla once daily for three months.
Ritaprevir, paritaprevir, ombetasvirDrug
Querevo for three months
Sofosbuvir and LedipasvirDrug
Once daily for three months
Salvage therapyDrug
three months in repeated treatment failure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with sustained virological response.Time frame: 2 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sherief Abd-Elsalam
Tanta, Egypt
Tanta university hospital
Tanta, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.